1 completed, 1 not yet recruiting, 1 recruiting. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Not yet recruiting 1, Recruiting 1 |
Follow REGN7508: new trials by email Literature Review of REGN7508 trials Research Report on REGN7508
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Healthy Adult Participants Trial Comparing Different Cenvacibart Presentations Cenvacibart - Healthy Volunteers | Phase 1 | Not yet recruiting | Regeneron Pharmaceuticals | 80 | 2026-11-23 | 2026-10-15 |
| Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis REGN9933, REGN7508, REGN9533 - End-Stage Kidney Disease (ESKD) | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 36 | 2026-09-17 | 2026-10-06 |
| Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants Aspirin, REGN9933, REGN7508 - Healthy Volunteers | Phase 1 | Completed | Regeneron Pharmaceuticals | 224 | 2024-09-30 | 2025-07-16 |
Hemorrhage (2) · Kidney Failure, Chronic (1) · Renal Insufficiency, Chronic (1) · Thrombosis (1)
Belgium (1) · United Kingdom (1)